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Perinatal route of transmission of human papillomavirus (HPV) has been demonstrated in several small
studies. We designed a large prospective cohort study (HERITAGE) to better understand perinatal HPV.
The objective of this article is to present the study design and preliminary data. In the ﬁrst phase of the
study, we recruited 167 women in Montreal, Canada, during the ﬁrst trimester of pregnancy. An addi-
tional 850 are currently being recruited in the ongoing phase. Cervicovaginal samples were obtained
from mothers in the ﬁrst trimester and tested for HPV DNA from 36 mucosal genotypes (and repeated in
the third trimester for HPV-positive mothers). Placental samples were also taken for HPV DNA testing.
Conjunctival, oral, pharyngeal and genital samples were collected for HPV DNA testing in children of
HPV-positive mothers at every 3–6 months from birth until 2 years of age. Blood samples were collected
in mother and children for HPV serology testing. We found a high prevalence of HPV in pregnant women
(45%[95%CI:37–53%]) and in placentas (14%[8–21%]). The proportion of HPV positivity (any site) among
children at birth/3-months was 11%[5–22%]. HPV was detected in children in multiple sites including the
conjunctiva (5%[10–14%]). The ongoing HERITAGE cohort will help provide a better understanding of
perinatal HPV.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomaviruses (HPVs) are unequivocally recognised
as the necessary cause of virtually all cervical cancers, of a sub-
stantial proportion of many other anogenital neoplasms (anal,B.V. This is an open access article u
arch Centre, Department of
éal, 3175 Côte Sainte-Cathe-
ottier).vaginal, vulvar, and penile cancers), of a non-negligible portion of
head and neck cancers (oral cavity, pharynx, and larynx) and are
also suspected to play a role in other neoplasms as well, such as
conjunctiva carcinoma [1–4]. HPVs also cause benign lesions such
as respiratory papillomatosis and anogenital condylomas [5,6].
HPV infection is the most common sexually transmitted infection
in the world. The prevalence of any cervical HPVs among cytolo-
gically normal women in the Americas has been estimated at 4.8%
[7] and can reach 30–50% among young sexually active women of
reproductive age [8,9]. Most HPV infections are asymptomatic andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Design and timeline for information and specimen collection. MFR: Medical ﬁle review. *HPV DNA testing repeated in the third trimester for HPV positive (at 1st
trimester) mothers only. **Only children of HPV DNA positive mother (at 1st trimester) were tested for HPV.
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persistent infection and even less to cancer, as most people will
clear the infection within 12–24 months [10].
Evidence suggests that newborns are exposed to HPV in the
perinatal period and can contract the infection. Vertical trans-
mission of HPV (perinatal infection) was ﬁrst reported in 1956 in a
case of juvenile laryngeal papillomatosis [11]. Conﬁrmation of the
perinatal transmission in different mucosa (genital, oral) was
subsequently supported in several studies, although the exact
mode of transmission is not well understood. Previous small stu-
dies have reported widely varying rates of infection in newborns,
with estimates ranging from 4% to 79% among day old infants born
to mothers testing positive for HPV during pregnancy [12–24].
There is a need for a better understanding of the rate and de-
terminants of perinatal transmission as well as the rate and de-
terminants of HPV persistence in children in a prospective study
with a large sample size and long term follow-up [25]. The in-
cidence of HPV-associated diseases, such as squamous cell carci-
nomas, has increased in children in recent years which may be, in
part, related to an increase in HPV prevalence in parents [26,27].
The impact of HPV on pregnancy outcomes also needs to be elu-
cidated. We undertook such a study on Human Papillomavirus
perinatal transmission and risk of HPV persistence among chil-
dren (HERITAGE study) to further our understanding of HPV
perinatal transmission and natural history of HPV infection. The
aim of this article is to present the study design and provide
preliminary data from this large prospective cohort study on the
perinatal transmission of HPV.2. Methods
2.1. Design and participants
HERITAGE is a prospective cohort study of pregnant women
recruited in academic hospitals and high volume obstetrical unitsin Montreal, Canada. Within each hospital, participants were re-
cruited in outpatient obstetric clinics catering to the local com-
munity. Pregnant women were accrued in the ﬁrst phase of the
study from November 2010 to June 2012 at Sainte-Justine hospital
centre, at the Centre Hospitalier de l′Université de Montréal
(CHUM) and at St-Mary's Hospital. For the extended phase, the
recruitment was from February 2015 to July 2016 in Sainte-Justine
hospital centre and the CHUM (and afﬁliated clinics). The ﬁrst
phase of HERITAGE was undertaken as an ancillary study of the
3D-study (Design, Discover, Develop), a prospective birth cohort of
the Integrated Research Network in Perinatology of Québec and
Eastern Ontario (IRNPQEO) network through the main university
hospitals afﬁliated with Québec's 4 medical faculties: Université de
Montréal, McGill University, Université Laval and Université de
Sherbrooke. Through a CIHR grant, the IRNPQEO network put in
place a cohort of 2366 pregnant women (recruitment between
2010 and 2012) in Quebec to address speciﬁc disease mechanisms,
while providing a comprehensive perspective of combined pre-
natal exposures on both birth outcomes and infant health until
2 year of age. Recruitment for HERITAGE was implemented in
3 teaching hospitals participating to IRNPQEO in Montreal (Sainte-
Justine, CHUM and St-Mary's Hospital) as a subsample of the 3D-
study.
Pregnant women 18 years of age and older and between 6 and
14 weeks of gestation (restricted to 18–30 years old women and 8–
14 weeks of gestation for the ﬁrst phase) and planning to give
birth in a participating hospital were eligible to be enroled in
HERITAGE. Exclusion criteria were: unable to provide informed
consent and HIV infection. The total number of women recruited
in phase 1 was 167 and an additional 850 are expected to be re-
cruited in the extended phase (phase 2). Pregnant women (re-
cruited during the ﬁrst trimester of pregnancy) provided samples
for HPV DNA (cervociovaginal samples at ﬁrst trimester and pla-
centa samples at birth) and for HPV serology. HPV DNA testing was
repeated in the third trimester for participants who tested positive
in the 1st trimester. Children of participants who tested HPV DNA
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cording to the timeline presented in Fig. 1. Additionally, children of
phase 1 were followed until 5 years of age (at 3, 4 and 5 year old)
for HPV DNA and HPV serology testing. Mothers signed an in-
formed consent form. Nurses and research staff were trained for
the collection of samples in adult and children participants and to
disclose and explain HPV DNA test results. The study protocol was
approved by the institutional ethical and research review boards
of the participating institutions.
2.2. Specimen and data collections
2.2.1. Swabs in pregnant participants and children for HPV DNA
testing
At the ﬁrst visit (recruitment), a self-collected cervicovaginal
specimen was obtained using a dry Dacron swab (Copan Italia S.p.
A) from pregnant mothers for type-speciﬁc HPV DNA testing
(Fig. 1). An additional self-collected cervicovaginal dry Dacron
swab for type-speciﬁc HPV DNA testing was obtained at a second
visit (at week 32–35) from mothers who were HPV positive in the
ﬁrst trimester. In children born from HPV-positive mother, speci-
mens were collected by a research nurse at 36–48 h (delayed from
birth to avoid contamination from the mother), and at 3, 6, 9, 12,
18 and 24 months. Scrapings for HPV DNA testing were collected
from the: 1) labia or prepuce and scrotum and anal region (genital
sample) (Dacron swab); 2) oral mucosa (buccal) (Dacron swab); 3)
pharyngeal mucosa (Dacron swab) as well as 4) from the con-
junctive using a soft swab (FLOQSwabs™, Copan Flock Technolo-
gies). For the conjunctiva, 2 samples were collected (one for left
eye and one for right eye). For the visit planned at 36–48 h after
birth, research nurses met mothers/children before they were
discharged from the hospital. Postnatal visits were all done at
Sainte-Justine Hospital. Mothers and children were asked to come
to Saint-Justine Hospital for the postnatal follow-up visits but
were also offered home-visits.
Swabs from women and children were rinsed individually in
1.5 ml of PreservCyt (Cytyc Corporation, Boxborough, MA) in a
plastic vial, DNA was puriﬁed with the Master pure procedure
[28,29] and stored at 70° until testing.
2.2.2. Swabs and biopsies on placenta for HPV DNA testing
At delivery, placenta brush and biopsy specimens were col-
lected for HPV DNA testing on both maternal and foetal side for
every participant. The placenta was collected after birth, rinsed in
tap water to remove excess blood and placed on the maternal side
so the cord (foetal side) was facing upward. Two cytology brushes
were used to collect cells from peripheral and central zones taking
the implantation of the cord as landmark. For each zone, two
biopsies (0.5 cm3) were then taken using scissors and clamps
(individual for each biopsy to avoid contamination). For maternal
side specimens, the placenta was turned over so the maternal side
faced upwards. Brush samples and biopsies (peripheral and cen-
tral) were taken according to the same procedure and care for
contamination. Virox™ was used to clean scissors, clamps and all
other tools after the procedure. Gloves were changed at each dif-
ferent step to avoid contamination: after the placenta was rinsed
and for specimen collection on each side (maternal and foetal). In
phase 2, two additional brush samples were collected from the
foetal side. For both peripheral and central zone, we collected a
brushing from the membrane and one after the foetal membrane
was removed. Biopsies were collected after the membrane has
been removed.
After specimen collection, swabs were placed directly into a
plastic vial with a liquid preservative, processed and stored as
described above. The biopsies were placed in cryogenic storage
tubes, processed and stored as described above.2.2.3. Blood in pregnant participants and children for HPV antibody
testing
At the ﬁrst visit, drops of blood on blotter were collected from
the mother for HPV antibodies testing (serum from women was
also collected in the ﬁrst phase in order to validate antibody
testing on blotter). A few drops of blood on blotter were also
collected from children at birth, 6, 12 and 24 months for HPV
antibodies testing. At birth, drops of blood were collected at the
same time as the heel-prick Guthrie test.
Drops of blood were collected on blotting paper (Whatman
903™, GE healthcare Ltd.) using a Contact-Activated Lancet (BD
Microtainer
s
) for both mother and children. After a minimum of
2–6 h at ambient air, the blotting paper was stored at 80°
pending transfer to the Laboratoire de Santé Publique du Québec
(LSPQ) for various HPV antibody testing. Serum collected from
mother was placed in cryogenic storage tubes and stored at 80°
until being transfer to the LSPQ.
2.2.4. Questionnaires and medical ﬁle review (MFR)
At entry, a questionnaire documented socio-demographic data
and pre-birth indicators including: age, ethnic group, marital sta-
tus, education, annual household income, gestational age at re-
cruitment, number of previous pregnancies, number of children,
age at ﬁrst pregnancy, medical history (HPV vaccination, abnormal
Pap test, history of colposcopy assessment, infertility, etc.), sexual
activity (lifetime number of sexual partners, age at ﬁrst inter-
course, number of sexual partner during the last year, etc.) and
smoking, alcohol and drugs consumption. During follow-up,
questionnaires and/or medical ﬁle review (MFR) documented ad-
ditional information on a range of variables during pregnancy
(update on medical history, Pap testing, sexual activity, number of
sexual relations per week, smoking, alcohol and drug consump-
tion) and at delivery (method of delivery, rupture of membrane,
labour length, cervix maturation method, induction method, epi-
siotomy, vaginal lacerations, neonatal information for the baby,
pregnancy outcome, preeclampsia, etc.). Questionnaires for post-
partum and follow-up visits collected information on breastfeed-
ing, child's height and weight, child's health, child's medication
and environmental exposures such as mother's alcohol, smoking
and drug consumption.
2.3. HPV DNA testing
The Linear Array HPV genotyping assay (LA-HP; Roche Mole-
cular Systems) was used to detect 36 mucosal HPV genotypes in-
cluding types 6, 11, 16, 18, 26, 31, 33, 34 (formerly known as type
64), 35, 39, 40, 42, 44 (formerly known as type 55), 45, 51, 52, 53,
54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84,
and 89. β-globin DNA was co-ampliﬁed to assess DNA integrity
and to screen for the presence of inhibitors [28,30–32]. Negative,
weak positive and strong positive controls were included in each
ampliﬁcation run. Extensive safeguards to avoid contamination
were used. Samples that were both β-globin and HPV-negative
were considered inadequate. HPV-52 was detected in the LA with
a probe that also cross-reacts with types 33, 35 and 58. Samples
reactive in the LA with the cross-reactive probe for HPV52 were
further tested with a validated HPV-52-speciﬁc real-time PCR as-
say [33]. HPV molecular variant analysis as well as measures of
HPV viral load will also be conducted in future studies.
2.4. Antibodies to HPV capsids testing
Blood samples collected on blotter from mothers (during
pregnancy) and children (at birth, and month 6, 12 and 24) were
tested for HPV antibodies using HPV Virus-Like Particle (VLP)-
Based Enzyme Immunoassay for seroreactivity to HPV types 6/11/
Table 1
Characteristics at enrolment of the 167 participants recruited in phase 1 of
HERITAGE.
Variables
Age Mean (SD): 26.9 (72.4)
Median (IQR): 27.5 (25.8–
28.6)
Race; n (%) White 130 (78.8)
Other 35 (21.2)
Education; n (%) Completed elementary 11 (6.6)
Completed secondary 23 (13.8)
College 47 (28.1)
University 75 (44.9)
Other/missing 11 (6.6)
Marital status; n (%) Married 43 (25.9)
Common law/living with a
partner
105 (63.3)
Single 16 (9.6)
Divorced 2 (1.2)
Annual household income; n (%) Low (r39,999$) 42 (26.1)
Middle low (40,000–59,999
$)
38 (23.6)
Middle high (60,000–
99,999$)
53 (32.9)
High (Z100,000$) 28 (17.4)
HPV vaccinated; n (%) No 156 (94.0)
Yes (all with Gardasil
s
(4 10 (6.0)
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thers were compared to validate HPV serology testing on blotter.
Testing was done at the LSPQ under the supervision of an expert in
serodiagnosis.
2.5. Statistical analysis
Descriptive analysis was used to describe prevalence of type-
speciﬁc HPV and groups of HPV (HR- and LR-types) among preg-
nant women, placenta and in children for phase 1. Mean, median,
inter-quartile range (IQR) were computed for continuous variables
and proportion (and 95% CI) was used for categorical variables.
Twelve genotypes are ofﬁcially recognised as High-Oncogenic
risk (HR-) HPV (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59)
according to their frequency of association with malignancy while
13 others are recognised as possibly HR-HPV according to the
latest classiﬁcation published by the World Health Organization's
International Agency for Research on Cancer (IARC) [34]. Other
classiﬁcations also categorised genotype, 66, 68, 73 and 82 as HR-
HPV [35,36]. In this study, for HPV groups, HPV-16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, 68, 73 and 82 were considered HR-
HPV, and HPV types 6, 11, 26, 34, 40, 42, 44, 53, 54, 61, 62, 67, 69,
70, 71, 72, 81, 83, 84 and 89 were considered as low oncogenic risk
(LR-HPVs) [34–36].types))
Lifetime smoking; n (%) No 105 (63.3)
Yes 61 (36.8)
Age ﬁrst sexual intercourse Mean (SD) 16.9 (72.8)
Median (IQR) 17 (16–18)
Number of lifetime sexual
partners
Mean (SD) 9.7 (76.5)
Median (IQR) 9.5 (3–16)
Number of sexual partners in the
last year
Mean (SD) 1.1 (70.8)
Median (IQR) 1 (1–1)
Type of deliverya; n (%) Spontaneous 109 (71.7)
Vaginal with vacuum 3 (2.0)
Vaginal with forceps 9 (5.9)
Caesarian-section 31 (20.3)
Gestational age Mean 39.5 (72.0)
Missing data excluded. n, number; SD, standard deviation; IQR, interquartile range.
a Excluded miscarriage, stillbirth.3. Results
Of the 207 women identiﬁed as eligible to participate in the
phase 1 of the HERITAGE study, 167 accepted to participate (par-
ticipation rate¼81%). Table 1 describes the characteristics at
baseline of the participants recruited in Phase 1. The mean and
median age of participating women were 26.9 years (SD72.4) and
27.5 years (Interquartile range (IQR)¼25.8–28.6), respectively.
Mean age was similar between HPV-positive and -negative women
(27.1 versus 26.7 years of age, respectively), the majority identiﬁed
as Caucasian (79%) and 94.0% were not vaccinated for HPV.
3.1. HPV DNA in pregnant women
The proportion of pregnant women who were HPV-positive at
the time of recruitment (ﬁrst trimester) was 45% [95% Conﬁdence
Intervals (CI): 37–53%] (75 out of 167). Of those, 80% [95% CI: 70–
88%] were still infected during the third trimester (60 out of 75).
From the 75 women infected at baseline, 56 (33.5% [95% CI: 26–
41%]) were infected with HR-HPV. There were 14 women (out of
the 75 infected at ﬁrst trimester) who acquired a new HPV type at
the second sampling (third trimester) (19% [95% CI: 11–29%]).
Multiple types were frequently detected among HPV-infected
women with 38 (out of 75) (51% [95% CI: 39–62%]) harbouring Z2
genotypes (range¼2–11). The mean number of genotypes detected
was 1.2 (SD¼1.8). Table 2 shows type-speciﬁc prevalence of HPV
among women at ﬁrst trimester.
3.2. HPV DNA in placenta
The overall prevalence of HPV in placental brush samples was
14% [95% CI: 8–21%] (Table 3). The prevalence of HPV in placental
brush samples for womenwho tested positive for HPV DNA during
the ﬁrst trimester was 27% [95% CI: 16–40%] whereas it was only
3% [95% CI: 0.3–10%] for those who tested negative during the ﬁrst
trimester.
The proportion of HPV-positive placental biopsies was lower
than placental brushes with an overall HPV prevalence of 5% [95%
CI: 2–10%]. A prevalence of 8% [95% CI: 3–18%] and 2% [95% CI: 1–
7%] was estimated among HPV-positive and -negative women inthe ﬁrst trimester, respectively (Table 3). Table 4 describes long-
itudinal type-speciﬁc infections (during pregnancy, in placental
samples (brush and biopsy) and in children at birth and/or
3 months) for women who were HPV-positive on placental sam-
ples or who had an HPV positive child. In our study, we detected
HPV on both sides of the placenta (foetal and maternal) and when
placental infection was detected, it was often with genotypes de-
tected in the cervicovaginal sample during pregnancy (14 out of 18
HPV positive placenta were infected with genotype(s) detected in
women during pregnancy).
3.3. Children
Overall, 67 children were tested for HPV at birth (from the 75
HPV-positive participating mother (89%)). The reason for missing
HPV results among offspring included miscarriage, stillbirth,
withdrawals and missing HPV DNA testing on the child at birth.
Table 5 shows the prevalence of HPV among children at birth and/
or 3 months of age. Interestingly, 4.8%, 8.1%, 1.6% and 4.8% of
samples were positive for HPV for conjunctival, oral, pharyngeal
and genital sites, respectively. Globally, seven (11.2% [95% CI: 4.7–
21.9]) children were HPV-positive in at least one site, some of
them testing positive at multiples sites (mouth, pharynx, genital
surface). One of the most novel ﬁndings of our study is the de-
tection of HPV in conjunctival samples of 3 children. One of them
was infected with the same genotype in both eyes (Table 4) and
Table 2
Prevalence of genotype-speciﬁc HPV infection among pregnant women at ﬁrst
trimester.
HPV genotype n % (n typeþ /n) 95% LCI 95% HCI
6 1 0.6 0.0 3.3
11 0 0.0a 0.0 2.2
16 10 6.0 2.9 10.7
18 7 4.2 1.7 8.4
26 0 0.0a 0.0 2.2
31 12 7.2 3.8 12.2
33 3 1.8 0.4 5.2
34 1 0.6 0.0 3.3
35 3 1.8 0.4 5.2
39 11 6.6 3.3 11.5
40 3 1.8 0.4 5.2
42 8 4.8 2.1 9.2
44 5 3.0 1.0 6.8
45 2 1.2 0.1 4.3
51 7 4.2 1.7 8.4
52 8 4.8 2.1 9.2
53 10 6.0 2.9 10.7
54 7 4.2 1.7 8.4
56 3 1.8 0.4 5.2
58 6 3.6 1.3 7.7
59 9 5.4 2.5 10.0
61 5 3.0 1.0 6.8
62 11 6.6 3.3 11.5
66 4 2.4 0.7 6.0
67 3 1.8 0.4 5.2
68 2 1.2 0.1 4.3
69 0 0.0a 0.0 2.2
70 2 1.2 0.1 4.3
71 2 1.2 0.1 4.3
72 0 0.0a 0.0 2.2
73 6 3.6 1.3 7.7
81 1 0.6 0.0 3.3
82 3 1.8 0.4 5.2
83 4 2.4 0.7 6.0
84 5 3.0 1.0 6.8
89 14 8.4 4.7 13.7
HPV groups
Any HPV 75 44.9 37.2 52.8
HR-HPV 56 33.5 26.4 41.2
LR HPV only 19 11.4 7.0 17.2
ß-globin negative 0 0
n, number; LCI, low conﬁdence interval; HCI, high conﬁdence interval; HR-, high-
oncogenic risk; LR-, low-oncogenic risk.
a One-sided, 97.5% conﬁdence interval.
Table 3
Prevalence of any HPV in placenta.
HPV in
placenta
Total HPV DNA positive
women at 1st
trimester
HPV negative women
at 1st trimester
n % (95%
CI)
n % (95% CI) n % (95% CI)
BRUSH
HPV positive 18 14% (8–
21)
16 27% (16–40) 2 3% (0.3–10)
HPV negative 112 86%
(79–92)
44 73% (60–84) 68 97% (90–99)
ß-globin neg 0 – 0 – 0 –
Total tested 130 60 70
Missinga 37
BIOPSY
HPV positive 6 5% (2–
10)
5 8% (3–18) 1 2% (1–7)
HPV negative 124 95%
(90–98)
55 92% (82–97) 69 98% (93–99)
Total tested 130 60 70
n¼Number.
a Missing results included pregnancy interruption, withdrawn, women who
gave birth to another hospital and missing HPV DNA testing on placenta at birth.
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pregnancy (and placenta) for the same HPV genotype.4. Discussion
We found a high prevalence (44.9%) of HPV at prenatal testing
in young pregnant women.
Furthermore, HPV was frequently detected in placenta samples
(14%). There was a non-negligible global prevalence (11.2%) of HPV
in newborns (at birth and/or at 3 months of age) from HPV-posi-
tive mother. This is also the ﬁrst study to report transmission of
HPV in children's conjunctiva. This interesting data lead to the
continuation of the study with an extended phase (phase 2) to
increase sample size. The data also seems to be in accordance with
recent small studies that report that perinatal transmission (oral
and/or genital) is between 4–22% [17,20,21,23,24]. In their meta-
analysis published in 2005, Medeiros et al., estimated the perinatal
transmission of HPV at 20% [37].
There are many reasons to explain the high prevalence of HPV
found in our cohort of pregnant women. First, cervicovaginal
samples were collected for which prevalence is expected to behigher than in cervical samples. The “wide area” sampling of the
lower genital track detects HPV in multiple foci in the cervical and
vaginal areas. Also, these are young women (18–30 years) who are
more likely to be infected than older women and they obviously all
had sexual activity (the most important risk factor for HPV) in a
near past as they are pregnant. Furthermore, a low proportion of
women were vaccinated against HPV and herd immunity is very
unlikely as the school-based vaccination programme in Quebec
started in 2008, a few years only before our study.
Perinatal transmission in different mucosa seems possible al-
though the exact mode of transmission is not well understood.
Most cases of vertical transmission may occur at delivery through
direct contact of the foetus with maternal infected cells during
vaginal delivery or at caesarean section following early membrane
rupture [25,38]. Transmission in utero is also possible through
ascending infection from mother's genital tract or HPV infected
semen present in the vagina following sexual intercourse [25,26].
Peri-conceptional transmission from male sexual partner is pos-
sible since HPV DNA has been detected in 8–64% of the seminal
ﬂuid and spermatozoa [25–39]. Moreover, HPV DNA has been
detected in the endometrium and ovaries. However, HPV trans-
mission to the embryos just after fertilisation remains theoretical
[25]. Transplacental transmission has also been supported as HPV
DNA was detected in amniotic ﬂuid with detection rates varying
between 15–65% [40–42]. HPV DNA has also been found in pla-
cental cells and in cord blood. The detection rate of HPV DNA in
trophoblastic cells varies from 0% to 60% [42–46] and from 0%
to13% in cord blood cells [23,44,46–48]. Recently, HPV DNA has
been detected in breast milk with a rate varying between 2–8%
[49–51] suggesting that HPV could be transmitted vertically to
neonates through breastfeeding. Finally, horizontal transmission
just after delivery can occur via digital contacts [26].
Risk factors for perinatal transmission are not well char-
acterised. The following factors have been associated with trans-
mission: viral load [52], lesions in maternal genital tract [53] and
maternal HPV infection with multiple genotypes [21,24]. Several
authors also reported a higher risk of transmission following a
vaginal delivery [17,21,24,41] but these results are controversial
[54]. Finally, very little is known about the effect of HPV on
pregnancy outcomes. In vitro experiments suggest that the
Table 4
HPV genotypes detected in women with placental infection or who delivered a children who was HPV positive.
During pregnancy Placenta Children (at birth and/or 3 month of age)
1st trimester 3rd trimester Swabs Biopsies Conjunctival Oral Pharyngeal Genital
Maternal sidea Foetal sidea Maternal sidea Foetal sidea
52, 62 52, 62, 89 89 89 – – – – – –
59 59 – 59 – – – – – –
16, 73 16 16, 39 – – – – – – –
66, 70, 89 66 66 – – – – – – –
16, 59 16, 59 16 16, 59 – – – – – –
31, 35, 42, 51, 53, 58 31, 35, 42, 51, 53, 58, 84 51 42, 51 – – – 39, 42 42 42
31, 34, 59 Missing samples 31, 68 31, 68 – 34, 68 31 31 – 31
39 39 39 – 39 – – – – –
– Missing samples 16 – 16 – – – – –
16 16 16 – – 16 – – – –
– Missing samples 16 – – – – – – –
53 53 53 – – – – – – –
66 16, 66 – 44 – – – – – –
51, 52, 53, 59, 67, 73, 82 51, 52, 53, 54, 59 51, 52, 53, 54 52, 53, 54 51, 52, 53 52, 53 – – – –
53 – – 53 – – – – – –
18, 31, 84 18, 31, 84 39 – – – – – – –
51 51 51 51 – 51 51 (both eyes) – – 51
33, 56, 73 33, 56 – 33, 56 – – – – – –
53 59 – – – – – 89 – –
89 89 – – – – – 89 – –
18 18 – – – – – 18
40, 42, 71, 83 40, 62, 71, 73, – – – – 62 – – –
–¼HPV negative.
a Included infection detected in peripheric and/or central zone.
Table 5
Number (and %) of children HPV positive (any of the 36 genotypes) at birth/3-
month visits.
Totala HPV positive
Conjunctive (left
and/or right eye)
Oral
(mouth)
Pharynx
(throat)
Genital
(surface)
All sites
combined
N % (95% CI) N % (95%
CI)
N % (95%
CI)
N % (95%
CI)
N % (95%
CI)
67 3 4.8%
(10.1–
13.5)
5 8.1%
(2.7–
17.8)
1 1.6%
(0.4–
8.6)
3 4.8%
(10.1–
13.5)
7 11.2%
(4.7–
21.9)
a Number of children tested for HPV from the 75 women who tested HPV
positive during pregnancy. Missing HPV results included miscarriage, stillborn,
withdraw and missing HPV DNA testing on child at birth.
H. Trottier et al. / Papillomavirus Research 2 (2016) 145–152150presence of HPV in trophoblastic cells could induce changes in
placental viability and adhesion [55]. Interestingly, some ob-
servational studies found that HPV was associated with sponta-
neous abortion [43,56,57]; others did not ﬁnd that association
[58]. Other studies linked the infection to prematurity [54] and
spontaneous preterm delivery [54,59,60]. Further studies on the
consequences of HPV infection in pregnancy outcomes are needed.
For example, to date, no clinical guidelines are in place to test
sperm donor for HPV. A better understanding of mechanisms of
transmission to the mother and her foetus could highlight the
need for such guidelines. Furthermore, a better understanding of
the development and persistence of HPV antibodies acquired
during childhood will improve the overall comprehension of the
natural history of HPV. Passively acquired immunity from ma-
ternal antibodies could also modulate acquisition and persistence
of infection in the infant.
The ﬁrst phase of our study is underpowered for an analysis of
risk factors or statistical associations. With a larger sample size
and a longer term follow-up, phase 2 of the HERITAGE study will
allow analysis of the rate and determinants of perinataltransmission as well as the rate and determinants of persistent
infection in children. With the completion of phase 2, we also
expect to have adequate power to verify associations such as as-
sociation between HPV infection and pregnancy outcomes as well
as between mode of delivery and HPV transmission. The recruit-
ment for the extended phase will end in September 2016. Ac-
counting for pregnancy duration and at least 2-years follow-up of
children, HERITAGE will provide ﬁnal data in 2019.Funding
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